Search PubMed⌕ Search

Biomedical subjects

E D Thomas

Publications and source records attributed to E D Thomas.

At least 19 recordsLinked to original sources
PubMed2001

Effect of corn silage hybrid on dry matter yield, nutrient composition, in vitro digestion, intake by dairy heifers, and milk production by dairy cows.

Three corn hybrids, Mycogen TMF94, Cargill F337 (which contains a brown midrib trait), and Pioneer 3861 were compared in a plot trial, an intake trial, and a lactation trial. In the plot trial, the three corn hybrids were planted in replicated 15.2 x 385-m plots. Mycogen TMF94 and Cargill F337 had lower yields of dry matter (DM), higher concentrations of neutral detergent fiber, and higher in vitro true DM disappearance compared with Pioneer 3861. Mycogen TMF94 had a higher yield of DM than Cargill F337 despite having a lower plant population. However, Cargill F337 had a higher in vitro true DM disappearance than Mycogen TMF94. In the intake trial, six individually penned Holstein heifers were blocked and assigned randomly to one of three total mixed rations containing 79% (DM basis) Mycogen TMF94, Cargill F337, or Pioneer 3861 corn silages in replicated 3 x 3 Latin squares. Heifers fed the Pioneer 3861-based TMR had lower DMI than heifers fed Mycogen TMF94 and Cargill F337-based TMR. In the lactation trial, 75 midlactation Holstein cows were blocked and assigned randomly to one of three total mixed rations containing 31% (DM basis) Mycogen TMF94, Cargill F337, or Pioneer 3861 corn silages used in the intake trial. Milk production was highest for cows fed Cargill F337-based total mixed rations. It is concluded from this study that Mycogen TMF94 was higher yielding, but less digestible, and resulted in lower milk production by lactating cows than Cargill F337. In addition, Mycogen TMF94 had higher in vitro true DM disappearance, and similar DM yield and milk production by lactating cows when compared with Pioneer 3861.

Animal Nutritional Physiological Phenomena↗
PubMed2001

Comparison of corn silage hybrids for yield, nutrient composition, in vitro digestibility, and milk yield by dairy cows.

A study was undertaken to compare Novartis N29-F1, a dual-purpose 90-d relative maturity corn hybrid, and Novartis NX3018, a 90-d relative maturity leafy corn silage hybrid for dry matter (DM) yield, in vitro digestibility, plant components, nutrient composition, and lactational performance by Holstein cows. The two corn hybrids were planted in replicated 15.2- x 321-m plots. Plant population and DM yield were similar between the two corn hybrids. Novartis NX3018 had higher content of crude protein and ash, a higher proportion of leaves and stalks, and a lower proportion of grain compared with Novartis N29-F1. The cob, grain, and leaves of Novartis NX3018 had higher in vitro true DM and neutral detergent fiber disappearances compared with the respective plant components of Novartis N29-F1. Thirty-eight midlactation multiparous Holstein cows (78 +/- 23.0 days in milk) producing 47.2 +/- 8.9 kg of milk per cow per day were blocked and assigned randomly to one of two total mixed ration (TMR) containing (DM basis) approximately 26% Novartis N29-F1 or Novartis NX3018 corn silage. Cows were housed in a free-stall barn and group fed ad libitum. The lactation study was conducted as a crossover design with two 28-d periods. Samples and data were collected during the final 7 d of each period. The total mixed rations were formulated using the Cornell-Penn-Miner Dairy nutrition model. Cows that were fed the total mixed rations containing Novartis NX3018 corn silage produced higher yields of milk 3.5% fat-corrected milk (FCM), milk crude protein, and milk lactose compared to cows that were fed the TMR containing Novartis N29-F1 corn silage. In conclusion, the Novartis NX3018 corn hybrid was leafier and more digestible in vitro, and when fed to dairy cows as silage, promoted higher milk yield compared with the Novartis N29-F1 corn hybrid.

Animals↗
PubMed2000

Landmarks in the development of hematopoietic cell transplantation.

The field of bone marrow transplantation has evolved over a period of 50 years. Reports of beneficial treatment of murine leukemia by irradiation and injection of marrow cells from another mouse stimulated interest in attempting to use these techniques to treat patients with leukemia. The first few bold attempts at human application were generally met with a total lack of success except for a few transplants involving identical twins. Understanding the HLA system led to the ability to select compatible sibling donors. The first successful long-term survivors were reported at the end of the 1960s. During the 1970's patients were given transplants for leukemia after failure of all other treatment. Survivals were poor, but some patients were cured. Transplantation early in the course of the disease resulted in greatly improved survival. During the 1980s improved control of infections, the use of peripheral blood as the source of stem cells, and the ability to select donors other than family members resulted in wide application of hematopoietic cell grafting.

Hematopoietic Stem Cell Transplantation↗
PubMed2000

Historic landmarks in clinical transplantation: conclusions from the consensus conference at the University of California, Los Angeles.

The transplantation of organs, cells, and tissues has burgeoned during the last quarter century, with the development of multiple new specialty fields. However, the basic principles that made this possible were established over a three-decade period, beginning during World War II and ending in 1974. At the historical consensus conference held at UCLA in March 1999, 11 early workers in the basic science or clinical practice of transplantation (or both) reached agreement on the most significant contributions of this era that ultimately made transplantation the robust clinical discipline it is today. These discoveries and achievements are summarized here in six tables and annotated with references.

Animals↗
PubMed1999

Bone marrow transplantation: a review.

Bone marrow transplantation has evolved over a period of 50 years. Laboratory observations and animal studies defined the essentials of transplantation biology. The first attempts to transfer these studies to patients met with little success. The definition of the complexities of the human leukocyte antigen (HLA) system made it possible to select compatible sibling donors and more recently unrelated donors. Transplantation of stem cells from marrow, blood, or cord blood is now the treatment of choice for a variety of hematological and genetic diseases. Transplantation using less toxic preparative regimens to induce mixed chimerism makes possible an application to autoimmune diseases. Laboratory and clinical research directed toward induction of tolerance and elimination of malignant cells point the way to a wider application of hematopoietic cell transplantation in the next decade.

Animals↗
PubMed1997

Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.

The influence of busulfan (BU) plasma concentration on outcome of transplantation from HLA identical family members for the treatment of chronic myelogenous leukemia (CML) was examined in 45 patients transplanted in chronic phase (CP) (n = 39) or accelerated phase (AP) (n = 6). All patients received the same regimen of BU, 16 mg/kg orally and cyclophosphamide (CY), 120 mg/kg intravenously. Plasma concentrations of BU at steady state (C(SS)BU) during the dosing interval were measured for each patient. The mean C(SS)BU was 917 ng/mL (range, 642 to 1,749; median, 917; standard deviation, 213). Of patients with C(SS)BU below the median, seven (five of 18 in CP and two of four in AP) developed persistent cytogenetic relapse and three of these patients died. There were no relapses in patients with C(SS)BU above the median. The difference in the cumulative incidence of relapse between the two groups was statistically significant (P = .0003). C(SS)BU was the only statistically significant determinant of relapse in univariable or multivariable analysis. The 3-year survival estimates were 0.82 and 0.64 for patients with C(SS)BU above and below the median (P = .33). There was no statistically significant association of C(SS)BU with survival or nonrelapse mortality, although the power to detect a difference in survival between 0.82 and 0.64 was only 0.24, similarly C(SS)BU above the median was not associated with an increased risk of severe regimen-related toxicity. We conclude that low BU plasma levels are associated with an increased risk of relapse.

Adult↗
PubMed1997

Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation.

Thirty-six patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) were studied for the presence of the bcr-abl fusion mRNA transcript after an allogeneic matched related (N = 12), partially matched related (N = 4), matched unrelated (N = 14), autologous (N = 5), or syngeneic (N = 1) bone marrow transplant (BMT). Seventeen were transplanted in relapse, and 19 were transplanted in remission. Twenty-three patients had at least one positive bcr-abl polymerase chain reaction (PCR) assay after BMT either before a relapse or without subsequent relapse. Ten of these 23 relapsed after a positive assay at a median time from first positive PCR assay of 94 days (range, 28 to 416 days). By comparison, only 2 relapses occurred in the 13 patients with no prior positive PCR assays; both patients had missed at least one scheduled follow-up assay and were not tested 2 months and 26 months before their relapse. The unadjusted relative risk (RR) of relapse associated with a positive PCR assay compared with a negative assay was 5.7 (95% confidence interval 1.2 to 26.0, P = .025). In addition, the data suggest that the type of bcr-abl chimeric mRNA detected posttransplant was associated with the risk of relapse: 7 of 10 patients expressing the p190 bcr-abl relapsed, compared with 1 of 8 who expressed only the p210 bcr-abl mRNA (P = .02, log-rank test). The RR of p190 bcr-abl positivity compared to PCR-negative patients was 11.2 (confidence interval 2.3-54.8, P = 0.003), whereas a positive test for p210 bcr-abl was apparently not associated with an increased relative risk. In separate multivariable models, PCR positivity remained a statistically significant risk factor for relapse after separately adjusting for donor (unrelated and partially matched v matched, autologous, and syngeneic), remission status at the time of transplant, the presence of acute graft-versus-host disease (GVHD), and type of conditioning regimen (total body irradiation dose of < or = 1,200 cGy v > 1,200 cGy). The PCR assay appears to be a useful test for predicting patients at high risk of relapse after BMT and may identify patients who might benefit from therapeutic interventions. The finding that the expression of p190 bcr-abl may portend an especially high risk of relapse suggests a different clinical and biologic behavior between p190 and p210 bcr-abl.

Acute Disease↗
PubMed1997

Stem cell transplantation: past, present and future.

The early attempts at human allogeneic marrow transplants in the 1950's and 1960's were largely unsuccessful. The probability of success has improved steadily in the past two decades. Cure rates now range from 90% for non-malignant diseases transplanted early to 15% for patients with advanced leukemia. Most marrow transplants have involved an HLA matched sibling donor but, more recently, a matched unrelated volunteer marrow donor can be found for many patients without a family donor. Current research is focused on new preparative regimens for elimination of malignant cells, better prevention of graft-versus-host disease, and the use of hematopoietic growth factors and cytokines. Autologous transplants, which use the patient's own marrow, are increasing, particularly for breast cancer. The hematopoietic stem cells are responsible for marrow regeneration after a transplant. Sufficient numbers of stem cells for transplantation can now be obtained from the peripheral blood after mobilization of these cells by chemotherapy or hematopoietic growth factors. Transplants can also be achieved using stem cells obtained from cord blood at the time of delivery, tissue typed, and cryopreserved for later use. A variety of technological advances has reduced the hospitalization time for transplant patients with a corresponding saving in cost.

Bone Marrow Transplantation↗